Wire2026 05 04Patients Remain Cancer Free Nearly 3 Years After Receiving Experimental Immunoth
1 outlet

Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy

Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.

First seen · 9:02 PM UTCMay 4, 2026

How it's being covered

Methodology →
LeftCenterRight
0Left · 0%0Center-Left · 0%0Center · 0%0Center-Right · 0%1Right · 100%

Covering this story

Sorted left → right

Also happening today

All today →

Also on this date in history

All →